دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?
doi : 10.1200/JCO.24.00829
2024, Volume 42 (34)
Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies
doi : 10.1200/JCO-24-01295
Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality
doi : 10.1200/JCO.24.00347
Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial
doi : 10.1200/JCO.24.00119
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
doi : 10.1200/JCO.23.02747
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial
doi : 10.1200/JCO.23.01836
Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial
doi : 10.1200/JCO.24.00099
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab
doi : 10.1200/JCO.24.00645
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
doi : 10.1200/JCO-24-01373
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926
doi : 10.1200/JCO.23.02510
US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations
doi : 10.1200/JCO.24.00427
Advancing Fertility Preservation in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy: Societal and Psychological Implications
doi : 10.1200/JCO-24-01204
Insights and Limitations of the Study on Temporary Interruption of Endocrine Therapy and Assisted Reproductive Technology Use in Breast Cancer Survivors
doi : 10.1200/JCO-24-01227
